JianYiBao Secures Tens of Millions in Pre-B Funding to Accelerate Prescription Benefit Programs

It is reported that Jianyibao, a comprehensive service platform for risk and health management of patients with pre-existing conditions, has recently completed a Pre-B financing round worth tens of millions of yuan and simultaneously launched its Series B fundraising. According to the announcement, this round was exclusively invested by Guoke Shunda Fund (a fund under CAS Holdings Group, the holding company of the Chinese Academy of Sciences). The proceeds will be primarily used to expand out-of-hospital channels for more original chronic disease medications and to implement consumer-facing pharmaceutical benefit products.

Previously, Jianyibao secured multiple rounds of financing from investors including Puhua Capital, Baidu Ventures, Zhongji Investment, and Weilai Capital.

As an investor in this round, the Guoke Shunda Fund has given full recognition to Jianyibao’s team and its “Healthcare + Pharmaceuticals + Insurance” business model, while also acknowledging the substantial scale of the niche health insurance market and Jianyibao’s leading position within the industry.

Since its establishment in 2017, Jianyibao has remained patient-centric, successfully bridging the cross-industry pain points among pharmaceutical companies, medication scenarios, and insurance and financial institutions. Leveraging its core competencies in professionalism, technology, and innovation, Jianyibao has enhanced the accessibility of innovative drugs and provided comprehensive coverage for individuals with pre-existing conditions.

The rising public awareness of health has gradually driven the overall development of the health insurance market. From 2011 to 2019, China’s gross written premiums for health insurance surged from RMB 69.2 billion to RMB 706.6 billion, representing a compound annual growth rate (CAGR) of 34%. Despite this rapid market expansion, most health insurance products cover only healthy individuals, whereas there is greater demand for health insurance among those with pre-existing conditions, particularly patients with chronic diseases.

In response, Jianyibao has partnered with insurance companies to launch medication insurance programs tailored to specific pharmaceutical products from drug manufacturers.

In fact, from the perspective of managing patients with pre-existing conditions, there is inherently strong synergy between insurance and pharmaceuticals. Therefore, in its product design, Jianyibao leverages pharmacy terminals as the entry point for insuring these patients, aiming to alleviate their financial burden caused by complications or adverse reactions. Meanwhile, it enhances medication adherence through coverage benefits, reduces the risk of disease progression, and ultimately achieves the goal of lowering overall healthcare expenditures.

In this process, not only was the issue of high medication costs for patients resolved, but pharmaceutical companies also gained access to patient medication data by integrating with Jianyibao, while retail pharmacies increased their sales volume, truly achieving a win-win outcome for all parties involved.

While continuing to benefit the market, Jianyibao is also constantly seeking change and innovation. With its team deeply rooted in the chronic disease medication sector and out-of-hospital channels for many years, Jianyibao is able to keenly perceive industry shifts and respond accordingly.

In recent years, driven by the “4+7” volume-based procurement (VBP) program and broader centralized procurement initiatives, the landscape of the pharmaceutical market has been continuously evolving, with the in-hospital market for innovative drugs also experiencing certain impacts. Against this backdrop, an increasing number of pharmaceutical companies have focused their efforts on seeking breakthrough opportunities in the out-of-hospital market and exploring new distribution channels.

In response to the current market landscape, Jianyibao has innovatively launched “Medication Freedom,” a retail commercial insurance product for chronic diseases. Reportedly, the most significant distinction between “Medication Freedom” and previous medication coverage or pay-for-performance models lies in its integration of medication discounts—of paramount concern to chronic disease patients—with flexible health insurance payment methods and lightweight health management services. This approach provides chronic disease patients with comprehensive medication benefits for an entire year, while also supporting pharmaceutical companies in accumulating and managing patients with high adherence. Furthermore, this product has increased Jianyibao’s average unit price from RMB 5 to over RMB 1,000, suggesting that the implementation of this product will drive substantial revenue growth for Jianyibao in the future.

In addition to the aforementioned products and services, Jianyibao has launched direct data connectivity and related projects for pharmaceutical companies, tailored to its existing business structure. This initiative provides real-time, segmented feedback on sales data from all monitored pharmacies to sales teams and management, offering data-driven support for the management, strategic planning, and resource allocation of pharmaceutical companies’ retail teams. Leveraging the team’s technical expertise, the number of directly connected pharmacy chains rapidly expanded from 100 to approximately 800 within six months, with coverage growing to around 200,000 stores. Monthly transaction orders on the direct connectivity platform have also surpassed one million. The increase in directly connected chain pharmacies lays the foundation for developing a more comprehensive drug benefit formulary and payment network in the future.

Currently, the health insurance industry in China is demonstrating a positive growth trajectory, with an increasing number of enterprises and capital investors placing their bets on this sector. Jianyibao has addressed multiple essential needs and pain points within the pharmaceutical industry chain through its robust operational capabilities and a business model that has gained widespread recognition.

Amid the surging tide of future market development, Jianyibao will continue to innovate and create value by addressing the core needs of patients with chronic diseases, while remaining committed to delivering high-quality pharmaceutical benefit products. Zhang Shengming, founder of Jianyibao, stated, “In the healthcare sector, it is essential to persevere, exercise patience, and focus on initiatives that truly benefit patients. Seeking quick gains often proves counterproductive; instead, we must prioritize businesses with long-term value.”